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Preferences of inflammatory arthritis patients for biological disease-modifying
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Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis
receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic.
Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for
rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of
COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical
characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19,
the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual
analog scale, [VAS]).
Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in
the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19.
Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the
patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity;
however, no difference was relevant for RA patients.
Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients
discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored.
Key words: COVID-19, biologic DMARDs, rheumatoid arthritis, spondyloarthritis

1. Introduction
The recent coronavirus disease 2019 (COVID-19)
pandemic is caused by severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2). Fever, dry cough, sore
throat, and muscle and joint pain are general disease
manifestations, and a severe clinical picture requiring
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hospital admission is encountered in 15%–20% of the
patients [1,2]. According to the data collected from
various countries, the COVID-19 fatality rate is about
1%–10% [3]. Patients with inflammatory arthritis such
as rheumatoid arthritis (RA) and spondyloarthritis (SpA)
regularly and continuously receive synthetic or biological
disease-modifying antirheumatic drugs (DMARDs) as
the main component of their treatment. On the other
hand, temporary discontinuation of particularly biological
DMARDs (bDMARDs) in the presence of infection is
an accepted recommendation [4]. Currently, the world
is reexperiencing a pandemic after a period of nearly
100 years. After March 11, 2020, when the World Health
Organization announced the pandemic, American,
European, and local societies of rheumatology have
claimed general recommendations about drug usage
[4–6]. The Turkish Society for Rheumatology released
COVID-19 recommendations on March 27, 2020, and left
the decision to use synthetic/biological DMARDs during
the pandemic mainly to the primary physician that follows
the patient [6]. On the other hand, the behavioral pattern
of patients with inflammatory arthritis using biological/
synthetic DMARDs during the COVID-19 pandemic is
unknown in Turkey or the rest of the world.
Accordingly, the present study aimed to evaluate
treatment adherence of patients with inflammatory
arthritis receiving bDMARDs within the first 100 days
after the announcement of the COVID-19 pandemic.
2. Methods
2.1. Patient selection
The TReasure registry is a web-based, prospective,
observational cohort including RA and spondyloarthritis
(SpA) patients from 17 centers in different regions of
Turkey and was established in December 2017. Details of
the establishment of TReasure registry were previously
reported [7]. As of March 2020, there were a total of 7471
patients with inflammatory arthritis (2560 RA patients and
4911 SpA patients) receiving bDMARDs in this registry.
The bDMARDs were as follows (arranged alphabetically):
abatacept, adalimumab, certolizumab, etanercept,
golimumab, infliximab, rituximab, secukinumab, and
tocilizumab.
The present study included patients who were
prescribed bDMARDs and for whom disease activity was
recorded within the 3-month period before the declaration
date of pandemic (March 2020) in the TReasure registry.
For rituximab therapy, this period was determined to be
6–9 months before the declaration date of the pandemic.
In the TReasure registry, the target population consisted
of 1871 patients, of whom 1394 (74.5%) completed the
standard phone questionnaire, 39 (2.1%) refused to
participate in the study, and the remaining could not be
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reached. The patients who participated and those who did
not participate in the study did not differ in demographic
and clinical characteristics (data not shown).
2.2. Demographic and clinical characteristics of the
patients
The demographic and clinical data collected from the
patients were defined previously [7]. In brief, the following
data were recorded for both RA and SpA patients: age, sex,
disease duration, comorbidities (the Charlson comorbidity
index), erythrocyte sedimentation rate (ESR) (mm/h),
C-reactive protein (CRP) level (mg/L), number of swollen
(66 joints) and tender (68 joints) joints, visual analog
scale (VAS)-pain score, patients’ global assessment-VAS,
and VAS-fatigue score, and the names of the currently
used synthetic DMARDs or bDMARDs. Additionally, in
RA patients, positivity for rheumatoid factor (RF) and
anticyclic citrullinated peptide (anti-CCP) was determined,
and the scores of the disease activity score-28 (DAS-28),
the Crohn’s Disease Activity Index (CDAI), the Simple
Disease Activity Index (SDAI), and the Health Assessment
Questionnaire (HAQ) were calculated to assess disease
activity. In SpA patients, the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI), the Bath Ankylosing
Spondylitis Functional Index (BASFI), and the Ankylosing
Spondylitis Disease Activity Score (ASDAS) based on CRP
(ASDAS-CRP) were used for the assessment of disease
activity. The diagnoses in SpA patients were classified
as ankylosing spondylitis (according to the modified
New York criteria), nonradiographic SpA (according to
the axial SpA criteria), peripheral SpA (according to the
peripheral SpA criteria), psoriatic arthritis (according to
the CASPAR criteria), and enteropathic arthritis (based
on the presence of inflammatory bowel disease [IBD] and
arthritis/sacroiliitis) [8–11]. In SpA patients, the positivity
of HLA-B27 and the presence of psoriasis, IBD, uveitis,
dactylitis, and enthesitis (according to the Leeds enthesitis
index [LEI]) were also recorded.
2.3. Questionnaire inquiring the pandemic period
A standard questionnaire was applied to the patients
via phone call. The phone calls were made in June 2020.
Accordingly, the following information questioned for the
period between March 10, 2020, and the day of phone call:
the presence of any signs of coronavirus infection; whether
or not being diagnosed with COVID-19; if diagnosed
with COVID-19, the place (hospital, home) where the
patient was followed up; whether or not being quarantined
due to COVID-19 infection; whether or not having
biological or synthetic DMARDs on hand; whether or
not the medications were administered during this time;
if not administered, the reason(s); whether or not being
contacted with his/her physician; and the current disease
activity. For the assessment of the current general health
status and disease activity, the patients were asked about
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their general health status (global patient assessment) and
to rate it from 0 (excellent) to 10 (very bad), and about
current disease activity, the patients were asked to rate
their disease activity as “completely under control”, “mild”,
“moderate”, “active”, and “highly active”.
2.4. Assessments in the study
In the present study, for the patients who discontinued
their bDMARDs, comparisons were performed for the
following parameters: age (also categorized in decades),
sex, mean disease duration (categorized as 1, 5, and 10
years), seropositivity, sequence of use of bDMARDs
(bDMARD-naïve, second-line, third-line), and usage of
anti-TNF versus nonanti-TNF bDMARDs. The disease
activity scores within the 3 months before the declaration
of the pandemic was also recorded; these included mean
DAS-28 score, CDAI, and SDAI scores (patients were
dichotomized as those with and without low disease activity
according to the DAS-28, SDAI, and CDAI scores), mean
HAQ score (patients were dichotomized according to the
scores of 0.5 and 1), mean BASDAI, BASFI, and ASDASCRP scores (patients were grouped according to ASDASCRP score), CRP level (<5 mg/L and >5 mg/L), patients’
global assessments-VAS score (grouping with 10-unit
intervals), general health status (completely under control,
mild, moderate, severe, highly severe), and presence of
suspected COVID-19. Patients’ global assessment-VAS
scores before the pandemic were compared with those
during the pandemic. Accordingly, an increase by >2 units
in the score was defined as worsened disease activity, and a
decrease by <2 units in the score was defined as improved
disease activity. Remission was defined as a general health
status-VAS score of ≤2, whereas active disease was defined
as a VAS score of ≥4.
Our study is compliant with the Helsinki Declaration
and approved by both the local ethical committee
(Hacettepe University; Approval number: 2020/08-25
(KA-17058)) and the Turkish Ministry of Health (Approval
number: 66175679-514.05.01-E.170548).
2.5. Patient and public involvement
There is no patient or public involvement in this study.
2.6. Statistical analysis
Data analyses were performed using the Predictive
Analytics SoftWare (PASW) 18.0 (SPSS Inc., Chicago,
IL, USA) for Windows. The variables were investigated
using visual (histogram, probability plots) and analytic
methods (Kolmogorov–Smirnov, skewness, and kurtosis)
to determine whether they are normally distributed
or not. The descriptive analysis data were expressed as
mean, standard deviation (SD), the median (minimummaximum), or percentages for categorical variables. Chisquare test or Fisher’s exact test was used for categorical
variables. Student’s t-test was used to compare normally

distributed variables, while the Mann–Whitney U test
was used to compare nonnormally distributed variables.
The variables identified with univariate analyses (p < 0.20)
were further entered the logistic regression analysis to
determine independent predictors of drug discontinuation
separately for RA and SpA patients. A p-value of <0.05 was
considered statistically significant.
3. Results
3.1. Demographic and clinical characteristics of the
patients
The demographic and clinical data and drug preferences
of 1394 patients who participated in the study are
presented in Table 1. In the RA group, RF was positive
in 267 (62.7%) patients, anti-CCP was positive in 206
(56.4%) patients, and RF and/or anti-CCP were positive
in 368 (74.5%) patients. In the SpA group, there were 664
(73.7%) patients with ankylosing spondylitis, 57 (6.3%)
patients with nonradiographic SpA, 101 (11.2%) patients
with peripheral SpA, 111 (12.3%) patients with psoriatic
arthritis, and 21 (2.3%) patients with enteropathic arthritis.
Extraarticular signs of the SpA patients were uveitis in 110
(12.5%) patients, IBD in 40 (4.6%) patients, and psoriasis
in 141 (16.1%) patients. The HLA-B27 positivity was
determined in 333 (59.1%) of 563 patients. Thirty-seven
(4.8%) patients had dactylitis, and 120 (19.3%) patients
had enthesitis (at least one entheseal region according to
the LEI). Of the RA patients, 233 (47.3%) were receiving
antitumor necrosis factor (TNF) agents, and 260 (52.7%)
were receiving nonanti-TNF bDMARDs. On the other
hand, of the SpA patients, 811 (90%) were receiving antiTNF agents, and 90 (10%) were receiving antiinterleukin
(IL)-17 treatment.
3.2. Detecting COVID-19 in the inflammatory arthritis
patients receiving bDMARDs
A total of 1353 patients were questioned about COVID-19
status. Of all the patients, 39 (2.8%) had at least one
suspicious sign of COVID-19, and 26 (1.9%) visited a
healthcare center for this reason (Table 2). Fever (body
temperature ≥ 38°C) was the suspicious sign in 14 (1.0%)
patients. The PCR test was positive for COVID-19 only
in 2 (0.15%) of all patients. Both of these patients were
treated at home.
3.3. Use of biological DMARDs during the pandemic
A total of 1362 patients responded to the question about the
continuation of bDMARDs during the pandemic. Overall,
247 (18.1%) patients discontinued their bDMARDs. Sixtysix (13.8%) of the RA patients and 181 (20.5%) of the
SpA patients discontinued their bDMARDs (p = 0.003).
The distribution of the patients who discontinued/did
not receive their bDMARDs is demonstrated in Table
3. Among RA patients, etanercept (%5.4) was the least
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Table 1. Demographic and clinical characteristics of the patients.

Female sex, n (%)
Age, years, median (range)
Disease duration, months, median (range)
ESR, mm/h, median (range)
CRP, mg/L, median (range)
Global assessment of health–VAS score, median (range)
Pain–VAS score, median (range)
Fatigue–VAS score, median (range)
HAQ score, median (range)
Number of swollen joints, mean ± SD
Number of tender joints, mean ± SD
DAS-28-ESR score, median (range)
CDAI score, mean ± SD
SDAI score, mean ± SD
BASDAI score, n (%)
BASFI score, n (%)
Hypertension, n (%)
Obesity, n (%)
Diabetes mellitus, n (%)
Hyperlipidemia, n (%)
Coronary artery disease, n (%)
COPD, n (%)
Asthma, n (%)
Malignancy, n (%)
Presence of at least1 comorbidity, n (%)
Presence of ≥2 comorbidities, n (%)
Presence of ≥3 comorbidities, n (%)
ASDAS–CRP, median (range)
Abatacept, n (%)
Adalimumab, n (%)
Certolizumab, n (%)
Etanercept, n (%)
Golimumab, n (%)
Infliximab, n (%)
Rituximab, n (%)
Secukinumab, n (%)
Tofacitinib, n (%)
Tocilizumab, n (%)
Hydroxychloroquine, n (%)
Leflunomide, n (%)
Methotrexate , n (%)
Sulfasalazine, n (%)

Patients with RA
n = 493

Patients with SpA
n = 901

400 (81.1)
55 (18–86)
131 (2–509)
16 (1–120)
3.96 (0.1–98.9)
30 (0–100)
30 (0–100)
30 (0–100)
0.38 (0–90)
0.58 ± 2.21
1.31 ± 3.41
2.55 (0.56–8.16)
7.97 ± 8.92
17.83 ± 20.08
–
–
143 (29.7)
166 (35.3)
48 (9.9)
71 (15.1)
20 (4.3)
11 (2.4)
26 (5.6)
5 (1)
186 (38.2)
121 (24.8)
167 (34.3)
–
32 (6.5)
89 (18.1)
38 (7.7)
75 (15.2)
18 (3.7)
13 (2.6)
40 (8.1)
–
77 (15.6)
111 (22.5)
164 (33.3)
117 (23.7)
135 (27.4)
23 (4.7)

398 (44.2)
43 (20–79)
111 (2–672)
12 (1–103)
3.84 (0.1–91.1)
25 (0–100)
20 (0–100)
20 (0–100)
–
0.1 ± 0.71
0.29 ± 1.6
–
–
–
1.55 (0–9.5)
1.2 (0–9.7)
137 (15.4)
220 (24.4)
57 (6.4)
98 (11.2)
17 (1.9)
3 (0.3)
28 (3.3)
8 (0.9)
462 (51.6)
229 (25.6)
160 (17.9)
1.84 (0–5.2)
–
270 (30)
146 (16.2)
182 (20.2)
90 (10)
123 (13.7)
–
90 (10)
–
–
13 (1.4)
17 (1.9)
57 (6.3)
71 (7.9)

RA, rheumatoid arthritis; SpA, spondyloarthritis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein, VAS, Visual Analog
Scale; HAQ, Health Assessment Questionnaire; DAS-28, the Disease Activity Score-28; CDAI, the Crohn’s Disease Activity Index; SDAI,
the Simple Disease Activity Index; BASDAI, the Bath Ankylosing Spondylitis Disease Activity Index; BASFI, the Bath Ankylosing
Spondylitis Functional Index; COPD, chronic obstructive pulmonary disease; ASDAS, Ankylosing Spondylitis Disease Activity Score;
SD, standard deviation.
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Table 2. Results of the questions about COVID-19 status in the study patients during the pandemic.
All patients
n = 1353

RA
n = 487

SpA
n = 866

Presence of any suspected sign of COVID-19

39 (2.8)

6 (1.2)

33 (3.7)

Admission to a healthcare center for suspected COVID-19

26 (1.9)

5 (1.0)

22 (2.5)

Having PCR testing for COVID-19

21 (1.6)

5 (1.0)

16 (1.8)

Quarantine recommendation for suspected COVID-19

10 (0.73)

0 (0)

10 (1.15)

PCR positivity for COVID-19

2 (0.15)

0 (0)

2 (0.23)

Family history of COVID-19 positivity

9 (0.66)

3 (0.6)

6 (0.7)

Data are presented as numbers (percentage, %).
COVID-19, coronavirus disease 2019; PCR, polymerase chain reaction.
Table 3. Distribution of the patients who discontinued their biological disease-modifying
antirheumatic drugs.
Patients with RA
n/N (%)

Patients with SpA
n/N (%)

All bDMARDs

66 (14.0)

181 (20.5)

Abatacept

4/31 (12.9)

NA

Adalimumab

15/86 (17.4)

46/264 (17.4)

Etanercept

4/74 (5.4)

38/180 (21.1)

Golimumab

3/18 (16.7)

15/86 (15.6)

Infliximab

2/12 (16.7)

29/118 (24.5)

Certolizumab

3/37 (8.1)

31/146 (21.2)

Rituximab

7/39 (17.9)

NA

Tofacitinib

6/75 (8.0)

NA

Tocilizumab

22/107 (20.5)

NA

Secukinumab

NA

22/89 (24.7)

Hydroxychloroquine

19/157 (12.1)

5/181 (2.8)

Leflunomide

14/113 (12.4)

4/181 (2.2)

Methotrexate

14/134 (10.4)

13/181 (7.2)

Sulfasalazine

2/22 (9.1)

13/181 (7.2)

RA, rheumatoid arthritis; SpA, spondyloarthritis; bDMARDs, biological diseasemodifying antirheumatic drugs; NA, not applicable.

frequently discontinued bDMARD, whereas tocilizumab
(%20.5) was the most frequently discontinued bDMARD.
The clinical characteristics and disease activity parameters
did not differ between the RA patients who discontinued
and those who did not discontinue their bDMARDs. In
the SpA patient group, those who discontinued their
bDMARDs were younger than those who did not (median
age, 40 years [range, 21–73 years] vs. median age, 44
years [range, 20–79 years]; p = 0.005). Moreover, the SpA
patients who continued their bDMARDs had lower disease

activity. The multivariate analysis revealed that age of <40
years, a poorer general health status, a poorer VAS score,
and the suspicion for the presence of COVID-19 were the
factors that determine the discontinuation of bDMARD
therapy in SpA patients (Table 4).
The data on the reasons for drug discontinuation were
available in 186 (75.3%) of 247 patients who discontinued
their bDMARDs. Of these patients, 60 (32.2%)
discontinued the therapy based on the recommendation
of his/her physician, 84 (45.1%) discontinued on their own
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Table 4. Characteristics of the patients with spondyloarthritis who discontinued their biological disease-modifying antirheumatic drugs
Patients with SpA Patients with SpA
Univariate Odds Ratio
who discontinued who continued
p
95% CI
bDMARDs
bDMARDs

Multivariate Odds ratio
p
95% CI

84 (46.4)

243 (34.6)

Completely under control 51 (28.2)

390 (55.8)

Mild

52 (28.7)

Moderate
Severe

Age (<40 vs. ≥40)

0.004

1.64 (1.18–2.28)

0.002

1.76 (1.24–2.51)

103 (14.7)

<0.001

3.86 (2.48–6.01)

<0.001

3.20 (1.99–5.15)

51 (28.2)

153 (21.9)

<0.001

2.55 (1.66–3.92)

0.003

2.03 (1.26–3.27)

21 (11.6)

41 (5.9)

<0.001

3.92 (2.15–7.15)

0.003

2.65 (1.38–5.10)

Extremely severe

6 (3.3)

12 (1.7)

0.010

3.82 (1.38–10.63)

0.103

2.46 (0.83–7.28)

VAS-PGA, <20 vs. ≥20

38 (21.1)

281 (40.2)

<0.001

2.51 (1.70–3.71)

0.016

1.74 (1.11–2.75)

Suspected COVID-19

12 (6.6)

20 (2.9)

0.019

2.41 (1.16–5.04)

0.136

1.83 (0.83–4.03)

General health status
Reference

Data are presented as numbers (percentage, %).
SpA, spondyloarthritis; bDMARDs, biological disease-modifying antirheumatic drugs; CI, confidence interval; VAS-PGA, visual analog
scale-patient global assessment; COVID-19, coronavirus disease 2019.

demand/fear, 13 (6.9%) discontinued due to suspected
COVID-19, 8 (4.3%) discontinued due to the lack of
disease activity, and 21 (11.3%) discontinued due to other
reasons. No difference was determined between RA and
SpA patients in terms of reasons for discontinuation of
bDMARDs. During the pandemic, 550 patients (213 RA
patients and 337 SpA patients) were able to communicate
with their physicians. The patients communicated
with their physicians through phone calls (314 [57.1%]
patients), face-to-face interview (203 [36.9%] patients),
text message (39 [7.1%] patients), e-mail (19 [3.5%]
patients), healthcare staff (assistant, nurse) (13 [2.4%]
patients), and relatives (5 [0.9%] patients). In 425 (77.3%)
of 550 patients, their physicians recommended them to
continue bDMARD therapy. In 37 (6.7%) of 550 patients,
their physicians recommended them to receive bDMARDs
on demand and/or to extent drug application intervals.
3.4. Disease activity during the pandemic
Evaluation of the disease activity during the pandemic
in all patients revealed that the disease was completely
under control in 46.8% of the patients (in 40.8% of the
RA patients and in 50.0% of the SpA patients), whereas
19.1% of the patients (21.7% of the RA patients and 17.7%
of the SpA patients) had mild disease activity, 24.7% of
the patients (27.9% of the RA patients and 23.1% of the
SpA patients) had moderate disease activity, 7.0% of the
patients (6.8% of the RA patients and 7.1% of the SpA
patients) had active disease, and 2.4% of the patients (2.9%
of the RA patients and 2.1% of the SpA patients) had very
high disease activity (p = 0.016). The mean general health

status-VAS score in all patients during the pandemic was
3.1 ± 2.5; it was 3.4 ± 2.6 in the RA patients and 2.9 ± 2.5
in the SpA patients (p < 0.001). The mean general health
status-VAS score in all patients in the prepandemic period
was 3.2 ± 2.5; it was 3.6 ± 2.6 in the RA patients and 3 ± 2.4
in the SpA patients (p < 0.001).
As compared with the period before the pandemic,
the ratios of patients with worsened disease activity,
those with improved disease activity, those in whom the
disease has become active (while in remission), those with
ongoing remission, those with ongoing active disease, and
those showing remission (while having active disease) in
the first 100 days of the pandemic are demonstrated in
Table 5. In the RA patients, these variables did not show
difference between the patients who discontinued and
those who did not discontinue their bDMARDs. In the
SpA patients, the ratio of those who remained in remission
before and during the pandemic was 32.1%. The rate of
drug discontinuation was lower in the SpA patients who
remained in remission (22.0% in those who discontinued
bDMARDs and 34.8% in those who did not discontinue
bDMARDs; p = 0.002); other parameters showed no
difference between the patients who discontinued and
those who did not discontinue bDMARDs.
4. Discussion
The COVID 19 pandemic, which was announced in March
2020 by the WHO, has directly influenced the daily life
of both healthy individuals and individuals with chronic
illnesses1. Immunosuppressed patients rank first among

World Health Organization (2020). The director-general’s opening remarks at the media briefing on COVID-19 [online]. Website https://www.who.
int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. [accessed 27 September 2020]).
1
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Table 5. As assessed according to the prepandemic period, changes in disease activity determined by the general health status-Visual
Analog Scale scores during the pandemic.
Status

Definition

Patients with RA
n = 428

Patients with SpA
n = 809

Worsened disease activity during the
pandemic

>2 units increase in the VAS score after
the pandemic as compared with before the
pandemic

100 (23.4)

137 (16.9)

Patients with improved disease activity
during the pandemic

<2 units decrease in the VAS score after
the pandemic as compared with before the
pandemic

89 (20.8)

118 (14.6)

While in remission before the pandemic,
becoming active during the pandemic

A VAS score of ≤2 before pandemic and ≥4
after the pandemic,

69 (16.1)

100 (12.4)

Remission both before and during the
pandemic

A VAS score of ≤2 before the pandemic and
≤2 after the pandemic

91 (21.3)

260 (32.1)

Active disease both before and during the
pandemic

A VAS score of ≥4 before the pandemic and
≥4 after the pandemic

121 (28.3)

175 (21.6)

Active disease before the pandemic,
remission during the pandemic

A VAS score of ≥4 before the pandemic and
≤2 after the pandemic

52 (12.1)

86 (10.6)

Data are presented as numbers (percentage, %).RA, rheumatoid arthritis; SpA, spondyloarthritis; VAS, visual analog scale; bDMARDs,
biological disease-modifying antirheumatic drugs; NA, not applicable.

the patient groups influenced by the pandemic most.
Biological DMARDs, which have been used in the last two
decades, have been the group of medications primarily
focused on due to their potential to increase the risk of
infection. The American College of Rheumatology (ACR)
and the European League Against Rheumatism (EULAR),
which are among the international expert societies
on rheumatology, have recommended identification
of the risk groups and continuation of bDMARDs as
long as possible within the frame of patient–physician
communication [4,5]. However, the pandemic has caused
severe anxiety and fear in some patients. Uncertainty and
fear were more prominent particularly in the early period
of the pandemic.
The present study investigated the therapeutic
approaches in the first 100 days after the declaration of
the pandemic in inflammatory arthritis patients known
to receive bDMARD therapy. It was observed that the
rate of confirmed COVID-19 cases (0.15%) was extremely
low in the first 100 days and that nearly 3% of the patients
needed to be evaluated for suspected COVID-19. The
first 100 days of the pandemic in Turkey was when a
strict lockdown was implemented particularly for the
people over the age of 65 and under the age of 18. In that
period, people with chronic illnesses in particular were on
administrative leave, and many patients self-quarantined
themselves. It is likely that such a low rate of COVID-19
determined among the patients with inflammatory

rheumatic diseases is associated with the abovementioned
strict lockdown. After that period, people began to return
to their normal life; therefore, how many of the patients
evaluated in the present study will develop COVID-19
infection during their follow-up is an investigation that
needs to be performed in the future.
Recent studies supported that patients who take
biological and conventional DMARDs have less morbidity
in the case of COVID-19 [2]. Moreover, in another study
from Turkey consisting of 167 patients with inflammatory
rheumatic disease, biologic and conventional DMARDs did
not seem to cause worse outcomes [12]. However, overall,
18% of all the inflammatory arthritis patients discontinued
bDMARDs in the first 100 days of the pandemic. It was
observed that drug discontinuation was more common,
particularly in the SpA patients, than in the RA patients.
Etanercept was the least frequently discontinued bDMARD
in the RA patients. It was understood that etanercept has
been used for longer than 20 years and thus considered
a relatively reliable therapeutic option for both patients
and physicians. The main reason for drug discontinuation
was the patients’ fear of bDMARD therapy; on the other
hand, drug discontinuation was recommended by the
physicians in one-third of the patients. In Italy, a survey
was conducted between February 2020 and April 2020 in
955 rheumatic patients [13]. In that patient group receiving
advanced treatment, modification of biological therapy was
performed in nearly 6% of the patients, which is quite low
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as compared with the finding of the present survey study.
Accordingly, different cultural factors can be considered
determinative. In the present study, among the patients
who were able to communicate with their physicians,
about 7% were recommended to receive treatment on
demand or could extent drug application intervals.
Receiving bDMARD therapy on demand or extending
drug application intervals is a method implemented by
clinicians for a long time in daily practice with efficacy
and safety proven in the controlled studies. During the
pandemic, the physicians preferred this method in some
of their patients. On the other hand, there is a patient
group trying to reach their physicians but could not reach
them. It was understood that a change occurred in the
physician–patient communication during the pandemic.
Specific to rheumatology, patients’ methods of reaching
their physicians should be dwelled on, and further studies
are needed on this subject.
Any factor that might explain bDMARD discontinuation
in the RA patients could not be determined. On the other
hand, it was observed that the SpA patients with the disease
under control were more likely to continue their drugs.
This finding is likely to indicate that the SpA patients with
the disease under control were more adherent to their
medications, and they avoided recurrent exacerbations.
Fluctuations in disease activity were observed in the first
100 days of the pandemic as assessed according to the
prepandemic period. The rate of remaining in remission
during the pandemic for the patients in remission before
the pandemic was 21% in the RA group and 32% in the
SpA group. It was understood that the patients with high
disease activity in the prepandemic period experienced
more difficulty in the early period of the pandemic.
The present survey study was conducted through
phone interviews. We could reach three-fourth of the
patients; the rates of drug discontinuation and COVID-19
might be higher among those that could not be reached;
thus, the results need to be evaluated within the scope of
this limitation. The fact that the information regarding
steroid use was not inquired could be considered another
limitation.
In conclusion, nearly one-fifth of the RA and SpA
patients recorded in the TReasure registry and known
to receive bDMARD therapy in the prepandemic period
discontinued their drugs in the first 100 days of the
pandemic. The frequency of COVID-19 was found
to be low in the first 100 days of the pandemic, which
corresponds to a period when a strict lockdown was
implemented in Turkey. Further investigations need to
be performed to find out what will happen when people
return to their normal active life. Although patients’ fear
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of treatment appeared to be the main factor, the treatment
was discontinued or also interrupted due to physicians’
recommendations. These treatment modifications in the
early period of the COVID-19 pandemic may appear as a
worsened disease activity in time. Treatment approaches
need to be monitored closely in the following period.
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